MOLOGEN AG
MOLOGEN AG with poster presentation at ASCO GI 2016
DGAP-News: MOLOGEN AG / Key word(s): Conference PRESS RELEASE N 2 / 2016 of 01/20/2016 MOLOGEN AG with poster presentation at ASCO GI 2016 Berlin, 20 January 2016 – The biotechnology company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) will present data on the immunotherapy MGN1703 at the 2016 Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, California (21 – 23 January, 2016). The poster will outline the design of the IMPALA trial including preliminary demographic data as well as stratification factors from the first 200 colorectal cancer patients randomized in the study. IMPALA started in September 2014 and is currently enrolling patients. Abstract details: For more information on the 2016 Gastrointestinal Cancers Symposium (ASCO GI) please visit the website: http://gicasym.org/ . About IMPALA Approximately 540 patients from more than 100 European centers in eight European countries, including the five major European pharma markets, will participate in the study. IMPALA started to treat the first patients in mid-September 2014. The study is expected to finish enrollment by the end of 2016. For more information on the trials IMPACT and IMPALA please visit www.clinicaltrials.gov. MOLOGEN AG The cancer immunotherapy lefitolimod (MGN1703) is the company’s lead product and best-in-class TLR9 agonist. Treatment with lefitolimod (MGN1703) triggers a broad and strong activation of the immune system. Due to this mechanism of action, lefitolimod (MGN1703) has the potential to be applied to various indications. Lefitolimod (MGN1703) is currently being developed for first-line maintenance treatment of colorectal cancer (pivotal study) and small cell lung cancer (randomized controlled trial). Furthermore it is also being investigated in a phase I study in HIV. MOLOGEN’s pipeline focus is on new innovative immunotherapies to treat diseases for which there is a high medical need. Memberships in associations: MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. Contact Note about risk for future predictions
2016-01-20 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | presse@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart | |
End of News | DGAP News Service |